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Abstract
Kaposi’s sarcoma (KS) is a common vascular tumor arising in human immunodefi ciency 
virus (HIV) infected patients and is one of the 27 conditions designated by the Centers 
for Disease Control as an acquired immunodefi ciency syndrome (AIDS) defi ning illness. 
Human herpes virus-8 (HHV-8), now called KS-associated herpes virus (KSHV), is a 
member of γ herpes virus family and is considered as the causative agent of KS. This 
review aims to discuss KS and its association with HIV/AIDS with an emphasis on oral 
features, the role of HHV-8/KSHV in causation of KS, and the current challenges faced 
in the management of the disease.
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Introduction
In 1869, Helmut Kobner, a German physician, appears to have 
been the fi rst to describe cases of metastatic cutaneous sarcoma. 
In 1872, the Hungarian physician, Moricz Kaposi, described an 
idiopathic, multi-pigmented, tumor-like lesion of the skin that 
eventually was named Kaposi’s sarcoma (KS).[1,2] During the 
19th century, KS was considered a rare disease and by the early 
20th century, an increased incidence was suggested.[2,3] KS is now 
a common vascular tumor arising in human immunodefi ciency 
virus (HIV) infected patients, and is one of the 27 conditions 
designated by the Centers for Disease Control as an acquired 
immunodefi ciency syndrome (AIDS) defi ning illness.[2,4] Human 
herpes virus-8 (HHV-8), also called KS-associated herpes virus 
(KSHV), a member of γ herpes virus family, is considered to be 
the causative agent of KS.[5]
Clinical features
Based on epidemiology and demographics, there are four variants 
of KS: (1) Classic KS that is relatively benign and predominantly 
occurs in elderly patients of Mediterranean, European, or Middle 
Eastern origin with a median age of >70 years; (2) an endemic or 
“African” form of KS that also occurs predominantly in men at a 
ratio of 3:1 with a peak median age of 35-39 years; (3) iatrogenic 
or post-transplant KS that may occur in HIV-seronegative 
immunocompromised individuals, long-term users of steroids 
and cytotoxic drugs, and individuals with autoimmune disorders; 
and (4) AIDS-associated KS. Although the four variants of KS 
are distinctive, they share similar clinical and histologic features, 
suggestive of the common pathogenesis.[5] In contrast to classic 
KS, which is often limited to the extremities, AIDS-associated KS 
frequently involves the mucocutaneous regions of the head and 
neck as primary sites, and visceral involvement is also present.[6] 
Mucocutaneous lesions of the head and neck region, occur in 
estimated 10% of AIDS patients.[7] The oral cavity is frequently 
involved with the hard and soft palate, gingiva, and tongue being 
the most common sites.[8,9] The prevalence of oral KS varies 
from 0 to 12% in Africa, and from 0 to 38% in United States and 
Europe.[10,11] Since the advent of AIDS, a high prevalence of oral 
KS is also noted in HIV-infected patients in Zimbabwe.[12]
Based on clinical appearance, AIDS-associated KS is classifi ed 
into six overlapping types: patch, plaque, telangiectatic, nodular, 
fl orid, and infi ltrative.[1,3,13,14] Oral lesions appear as red to 
purple macules, papules, or nodules that may ulcerate and cause 
local destruction.[9,15] Although the clinical behavior of AIDS-
associated oral KS is rather unpredictable, majority of the cases 
represent aggressive disease and have associated disseminated 
cutaneous and visceral lesions.[16] Slow growing oral tumors 
are generally associated with patients who have no additional 
complicating opportunistic infections.[17]
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Diff erential diagnosis
Early lesions of KS may be diﬃ  cult to distinguish from 
ecchymoses, nevi, dermatofi broma and lichen planus.[18] Nodular 
or plaque-like lesions overlying mucosa should be biopsied 
to rule out bacillary angiomatosis, hemangioma, pyogenic 
granuloma, angiosarcoma, or lymphangiosarcoma.[18,19]
Histopathology
The histogenesis of KS is diﬃ  cult to determine as lesions 
typically exhibit multiple cell types. The tumor is mainly 
composed of undiﬀ erentiated mesenchymal cells and spindle-
shaped cells.[20-23] The spindle cells, considered the tumor 
element, are of mesenchymal origin and have features that 
resemble both endothelial and smooth muscle cells.[22,23] The 
tumor cells may be derived from cells of either lymphatic 
or venous diﬀ erentiation.[17,22] Furthermore, biopsies of KS 
feature numerous slit-like vascular channels and may present 
extravasation of erythrocytes, hemosiderophages, eosinophilic 
hyaline inclusions, and infl ammatory infi ltrate.[9,20,21]
The histogenesis of the spindle cell component, believed 
to be the KS tumor cell, remains controversial; although many 
studies favor an endothelial cell origin.[22-24] Another highly 
debatable issue is whether KS is a clonal “neoplastic” lesion or 
whether it is “reactive” and polyclonal. Most of the evidence 
suggests that many KS lesions are hyperplastic and polyclonal in 
nature, but that either,
• These lesions contain a small proportion of clonal, neoplastic 
tumor cells that are diﬃ  cult to identify and culture, or
• Some of these polyclonal lesions may undergo full 
transformation during disease progression, probably when 
an actively proliferating cell acquires genetic alterations that 
provide a selective advantage, leading to the emergence of a 
truly neoplastic clone in the minority of cases of KS.[24]
Role of HHV-8/KSHV and HIV
Multiple agents, including cytomegalovirus, hepatitis-B virus, 
HHV-6, HIV, and Mycoplasma penetrans, have been suspected 
in the past as causing KS; but none of these have been clearly 
shown to present in most cases and to have a causal association 
with KS.[24] Thus, although an infectious origin has long been 
suspected, it was only in 1994 that HHV-8/KSHV was fi rst 
detected in KS specimens.[25] KSHV is now considered the 
causative agent of AIDS-associated, classic, endemic, and 
iatrogenic KS. In addition, it is also believed to be the causative 
agent of primary eﬀ usion lymphomas (body cavity-based 
lymphomas),[26] multicentric Castleman’s disease,[26,27] and 
possibly oral plasmablastic lymphomas.[28]
Serological studies have indicated that unlike other HHVs, 
KSHV is not ubiquitous.[26] The seroprevalence of KSHV is 
low in the United States and parts of Europe (ranging from 0 to 
20%), rising in Mediterranean countries to reach levels >50% 
in some geographic regions of Africa.[12] In North America 
and Europe, primary infection with KSHV mainly occurs 
among adult homosexual men and is transmitted principally 
via sexual contact; the KSHV seroprevalence being associated 
with the number of sexual partners and sexual practices.[12,26] 
Transmission of KSHV via saliva has also been documented.[29] 
In African populations, KSHV infection seems to occur largely 
before puberty through casual family and community contacts; 
oral secretions being a potential vehicle of non-sexual horizontal 
spread; vertical transmission of KSHV being insignifi cant.[12,26] 
A recent study conducted in Malawi, Africa, has also shown that, 
apparently, healthy people in regions where KSHV is endemic 
can be infected by multiple strains.[30] However, it is still unclear 
if this refl ects a simultaneous co-infection by several KSHV 
strains, reactivation of latent strains or superinfection.[30]
KSHV is lymphotropic and is more closely related to 
Epstein–Barr virus and herpesvirus saimiri than to other herpes 
viruses.[5,27] The KSHV genome contains several genes related to 
cellular genes involved in cell proliferation and host responses 
that probably contribute to viral pathogenesis.[26,31]
The pathogenesis of AIDS-associated KS is multifactorial 
and involves KSHV, altered expression and response to 
cytokines and stimulation of KS growth by HIV trans-activation 
protein (tat).[32,33] KSHV is a necessary but solely not a suﬃ  cient 
cause of KS.[34] It encodes protein homologs of interleukin-6, 
chemokines of the macrophage infl ammatory protein family, cell 
cycle regulators of the cyclin family, and anti-apoptotic genes of 
the bcl-2 family.[26] The HIV tat protein can promote the growth 
of spindle cells of endothelial origin but only in the presence 
of infl ammatory cytokines.[32,33] The synergistic relationship 
between infl ammatory cytokines and HIV tat protein, when 
combined with the immunosuppression associated with AIDS, 
may provide an explanation for aggressive nature of AIDS-
associated KS compared to relatively non-aggressive, classic 
Mediterranean form in which the HIV tat protein does not play 
a role.[33] The sequence of events creating the infl ammatory 
angiogenic environment has been described by Dezube[33] as 
follows: (1) circulating KS progenitor cells and cells latently 
infected with KSHV seek sites of pre-existing infl ammation; 
in the case of oral KS, pre-existing infl ammation may include 
acute and/or chronic periodontal disease sites; (2) exposure 
to infl ammatory cytokines such as interferon-α (IFN-α) results 
in diﬀ erentiation of latently infected cells into KS-like spindle 
cells and induces KSHV reactivation; (3) reactivation of KSHV 
leads to expression of potentially pathogenic genes such as 
viral interleukin-6 that in turn, can activate vascular endothelial 
growth factor and induce angiogenesis; (4) viral lytic replication 
in the same cells activates infl ammation, which also may play 
a role in angiogenesis; (5) the creation of infl ammatory-
angiogenic environment increases the availability of infectable 
cells, i.e. endothelial and KS spindle cells, which are then 
included in the development of the lesion; (6) cells also become 
responsive to HIV tat protein; and (7) the HIV tat protein 
augments the infl ammatory-angiogenic state by the increasing 
angiogenic activities of basic fi broblast growth factor, IFN-α, and 
vascular endothelial growth factor by mimicking the eﬀ ects of 
Rao Kaposi’s sarcoma: A review
3
the external matrix proteins fi bronectin and vitronectin and by 
increasing the expression of matrix metalloproteinases.
Prognosis and management
The prognosis of patients with AIDS-associated KS is often 
actually dependent on factors other than the tumor itself. In 
1989, the AIDS trial council group devised the TIS staging 
system, based upon the extent of tumor (T), the status of 
immune system i.e. CD4+ T-cell count (I), and the presence of 
other HIV/AIDS-associated systemic diseases (S).[12]
At present, there is no specifi c treatment for AIDS-associated 
KS. Treatment is thus directed towards the elimination, or at least 
reduction of cosmetically unacceptable lesions, pain, and edema, 
as well as providing relief from symptoms caused by systemic 
involvement.[33] Local therapy may be eﬀ ective for a limited form of 
the disease, but systemic therapy is required for disseminated, severe 
forms of KS.[33] Highly active anti-retroviral therapy (HAART) is 
useful in the management of AIDS-associated KS. It can eﬀ ectively 
reduce the viral load (HIV) and thereby raise the CD4+ T-cell 
count, the two factors which contribute to the causation of KS. 
Thus, HAART causes fall in KSHV levels in the blood presumably 
due to a reduction in HIV-induced immunosuppression and HIV/
KSHV-mediated oncogenesis.[12] Reports also suggest a reduced 
incidence of KS in HIV-infected individuals treated with HAART 
that includes at least one protease inhibitor. Both in vivo and in vitro 
studies have proved the fact that protease inhibitors have a direct 
anti-angiogenic, anti-tumor activity.[12]
Older treatment modalities for managing oral KS have been 
surgical/laser therapy, local irradiation, intra-lesional injections 
of sodium tetradecyl sulfate, and chemotherapy with vinca 
alkaloids, paclitaxel and liposomal anthracyclines. However, only 
fi ve agents are commonly used with success for the treatment of 
KS: Alitretinoin gel for topical therapy, liposomal daunorubicin 
and oloxorubicin, paclitaxel, and IFN-α for systemic therapy.[12]
The strong angiogenic component of KS makes it particularly 
suitable for treatment with drugs that have anti-angiogenic 
action, such as thalidomide, matrix metalloproteinases, and IM-
862. Based on the apoptotic and anti-proliferative activity of 
iron chelation on KS cells, it is also suggested that withdrawal 
strategies may be eﬀ ective.[12]
Direct antiviral approaches targeting KSHV have also been 
proposed. In vitro studies have shown that KSHV is very sensitive 
to cidofovir, moderately sensitive to ganciclovir, but only weakly 
sensitive to acyclovir. However, their eﬃ  cacy in vivo is yet to 
be corroborated. IFN-α may inhibit infection or reactivation 
by KSHV. Single-agent therapy with IFN-α is associated with 
signifi cant toxicity, but when used in combination with anti-
retroviral agents, may have signifi cant eﬀ ects on disseminated, 
but non-rapidly progressive KS.[12]
Conclusions
Studies pertaining to KS suggest epidemiologic patterns that 
are consistent with a sexually transmitted agent, before a viral 
agent HHV-8/KSHV was identifi ed, and that it is strictly 
not an opportunistic infectious agent related to HIV/AIDS-
associated KS. Immune suppression along with genetic and/or 
environmental factors may interplay in variable combinations in 
the eventual causation of KS.
Currently, a wide array of treatment modalities for KS, are 
aimed at elimination of cosmetically unacceptable lesions, 
reduction of unsightly edema and lymphadenopathy, and to 
alleviate symptoms caused by systemic involvement.
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